about
Toxicities and Adverse Drug Reactions Experienced During Anticancer Treatment: It Is Desirable to Consider the Problem Within the International System of Pharmacovigilance.Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations.An historical overview over PharmacovigilanceEU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodiesPharmacovigilance workflow in Europe and Italy and pharmacovigilance terminologyPharmacovigilance in oncologyTargeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilanceAn Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative ReviewSafety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung CancerPharmacovigilance of anti-cancer medicines: opportunities and challenges
P50
Q48985530-B8200EEF-3B98-4F1E-BC88-86C529B8DCB8Q51034561-0209360E-F550-4A21-BD36-FBEEF9DD2801Q57172382-0C02A80F-D9EB-413B-B3EE-A2D51556341CQ58792200-0EE78FFD-7DE8-42C5-899B-1559D69FE857Q58792204-EB4792F6-22B1-41C7-B4AD-62ED57A99790Q58804356-B14DD922-F5B2-4BFC-9D77-D8AEB05D2364Q88766822-FC962A8C-0D6D-445C-96CD-4D5A777F4552Q91460249-26B532AB-DFFC-405B-8862-01E81C8F1CC5Q92292327-DA276CDD-BEA8-4130-B480-B5BB9DEF4CFEQ96581984-6C7926D6-4EA9-4F1E-958D-9BB0B08A4A96
P50
description
researcher ORCID ID = 0000-0001-8042-7773
@en
wetenschapper
@nl
name
Sara Francescon
@ast
Sara Francescon
@en
Sara Francescon
@es
Sara Francescon
@nl
type
label
Sara Francescon
@ast
Sara Francescon
@en
Sara Francescon
@es
Sara Francescon
@nl
prefLabel
Sara Francescon
@ast
Sara Francescon
@en
Sara Francescon
@es
Sara Francescon
@nl
P1153
56835618200
P21
P31
P496
0000-0001-8042-7773